Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SABBOBCATon Feb 28, 2023 12:51pm
313 Views
Post# 35310085

Tinfoil Hat

Tinfoil Hat

I find that my theories are getting wilder by the day and I need a tinfoil hat...

So in terms of delayed earnings, optically it looks like the cause was the Marathon negotiation. However, TH would have known they were short on cash, hence the ATM activity in Q4 and likely could have already started talks at an early stage.

Alternatively, TH could be disguising the "blackout period". As earning butt up against the end of Q1, the blackout period is now extended again. This keeps TH from tipping its hand by needing to say the blackout period is extended due to ongoing partner/deal related negotiations. 

I know it is pretty crazy, but I just struggle to rationalize how the BoD or Management can remain intact while taking risky bets and watching the SP implode. Or do we need to start a #DawnIsGone #BringBackLuc campaign to get some in the Chair that will take a diciplined apporach to value creation. 

<< Previous
Bullboard Posts
Next >>